Redefining glucose thresholds for hypoglycaemia management in children and young adults with type 1 diabetes on automated insulin therapy: A cross‐over clinical trial protocol

Background and Aim Current international guidelines for hypoglycaemia management in Type 1 diabetes recommend initiating treatment when glucose level falls below 3.9 mmol/L. However, these recommendations were developed before widespread use of diabetes technologies. This study aims to determine whether a revised hypoglycaemia treatment approach incorporating a lower treatment threshold is non‐inferior to the standard threshold (<3.9 mmol/L) in children and young adults with Type 1 diabetes using automated insulin delivery (AID) systems. We hypothesise that the revised approach will be non‐inferior to the current standard recommendations without increasing time in clinically significant hypoglycaemia. Methods This single‐centre, randomised, two‐period, crossover, non‐inferiority trial will recruit 45 participants aged 6–25 years with Type 1 diabetes, diagnosed for at least 12 months and using AID systems. Participants will complete two 4‐week treatment periods in random order: standard hypoglycaemia treatment (<3.9 mmol/L) and revised hypoglycaemia treatment (≤3.6 mmol/L with consideration of CGM trends, active insulin, exercise and symptoms). Treatment periods will be separated by a 2‐week washout period. The primary outcome is the percentage of time spent in clinically significant hypoglycaemia (<3.0 mmol/L), measured using CGM. Secondary outcomes are CGM metrics including time in range and time above range, along with participant acceptability of the revised treatment approach. Conclusion This study will provide prospective evidence on whether a revised hypoglycaemia treatment approach can safely reduce the glucose threshold for treatment in children and young adults using AID systems. Findings may inform future recommendations for hypoglycaemia management in the era of diabetes technologies.

Authors

Institutions

Publication Details

Journal
Diabetic Medicine
Published
2026-11-19
DOI
https://doi.org/10.1111/dme.70536
Primary Topic
Diabetes Management and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Redefining glucose thresholds for hypoglycaemia management in children and young adults with type 1 diabetes on automated insulin therapy: A cross‐over clinical trial protocol

Timothy William Jones, Elizabeth Ann Davis, Mary Binsu Abraham, Grant J. Smith et al.
Diabetic Medicine
Diabetes Management and Research
article

Redefining glucose thresholds for hypoglycaemia management in children and young adults with type 1 diabetes on automated insulin therapy: A cross‐over clinical trial protocol

Timothy William Jones, Elizabeth Ann Davis, Mary Binsu Abraham, Grant J. Smith, Barbara Keating, Julie Dart, Peter William James Delaney
article en

Abstract

Background and Aim Current international guidelines for hypoglycaemia management in Type 1 diabetes recommend initiating treatment when glucose level falls below 3.9 mmol/L. However, these recommendations were developed before widespread use of diabetes technologies. This study aims to determine whether a revised hypoglycaemia treatment approach incorporating a lower treatment threshold is non‐inferior to the standard threshold (<3.9 mmol/L) in children and young adults with Type 1 diabetes using automated insulin delivery (AID) systems. We hypothesise that the revised approach will be non‐inferior to the current standard recommendations without increasing time in clinically significant hypoglycaemia. Methods This single‐centre, randomised, two‐period, crossover, non‐inferiority trial will recruit 45 participants aged 6–25 years with Type 1 diabetes, diagnosed for at least 12 months and using AID systems. Participants will complete two 4‐week treatment periods in random order: standard hypoglycaemia treatment (<3.9 mmol/L) and revised hypoglycaemia treatment (≤3.6 mmol/L with consideration of CGM trends, active insulin, exercise and symptoms). Treatment periods will be separated by a 2‐week washout period. The primary outcome is the percentage of time spent in clinically significant hypoglycaemia (<3.0 mmol/L), measured using CGM. Secondary outcomes are CGM metrics including time in range and time above range, along with participant acceptability of the revised treatment approach. Conclusion This study will provide prospective evidence on whether a revised hypoglycaemia treatment approach can safely reduce the glucose threshold for treatment in children and young adults using AID systems. Findings may inform future recommendations for hypoglycaemia management in the era of diabetes technologies.

Diabetic Medicine
The Kids Research Institute Australia (AU), The University of Western Australia (AU), Princess Margaret Hospital for Children (AU), Perth Children's Hospital (AU)
Diabetes Management and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon